Biomerica Operating Margin from 2010 to 2024
| BMRA Stock | USD 0.40 0.01 2.44% |
Check Biomerica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomerica's main balance sheet or income statement drivers, such as Depreciation And Amortization of 212 K, Interest Expense of 32.2 K or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 2.74, Dividend Yield of 0.0 or PTB Ratio of 2.3. Biomerica financial statements analysis is a perfect complement when working with Biomerica Valuation or Volatility modules.
Biomerica | Operating Margin |
Latest Biomerica's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Biomerica over the last few years. It is Biomerica's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomerica's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.76) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Biomerica Operating Margin Regression Statistics
| Arithmetic Mean | (0.42) | |
| Coefficient Of Variation | (114.07) | |
| Mean Deviation | 0.39 | |
| Median | (0.24) | |
| Standard Deviation | 0.48 | |
| Sample Variance | 0.23 | |
| Range | 1.4359 | |
| R-Value | (0.87) | |
| Mean Square Error | 0.06 | |
| R-Squared | 0.75 | |
| Significance | 0.000029 | |
| Slope | (0.09) | |
| Total Sum of Squares | 3.21 |
Biomerica Operating Margin History
About Biomerica Financial Statements
Biomerica stakeholders use historical fundamental indicators, such as Biomerica's Operating Margin, to determine how well the company is positioned to perform in the future. Although Biomerica investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biomerica's assets and liabilities are reflected in the revenues and expenses on Biomerica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biomerica. Please read more on our technical analysis and fundamental analysis pages.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection andor treatment of medical conditions and diseases worldwide. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Biomerica operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomerica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomerica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomerica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomerica Stock:Check out the analysis of Biomerica Correlation against competitors. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 0.327 | Quarterly Revenue Growth 0.055 | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.